Edwards Lifesciences Corporation(EW)Earnings, Financials & Key RatiosEdwards Lifesciences Corporation (EW) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the 16.7% revenue growth in 2026Q1 is impressive, the current 49.61 P/E ratio and the recent $501.5 million working capital drag warrant caution regarding near-term cash generation.
Edwards Lifesciences Corporation (EW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Edwards Lifesciences Corporation (EW) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 23, 2026 | $0.78vs $0.73+7.0% | $1.6Bvs $1.6B+3.2% |
| Q1 2026 | Feb 10, 2026 | $0.58vs $0.62-6.1% | $1.6Bvs $1.5B+1.5% |
| Q4 2025 | Oct 30, 2025 | $0.67vs $0.60+12.4% | $1.6Bvs $1.5B+3.7% |
| Q3 2025 | Jul 24, 2025 | $0.67vs $0.62+7.4% | $1.5Bvs $1.5B+3.0% |
Recent stock market news and headlines for Edwards Lifesciences Corporation (EW)
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense today announced the launch of the SWH1530VP, a next-generation dual-enclave 100/40 Gigabit Ethernet switch engineered to provide secure, deterministic, and high-performance networking for modern Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, Reconnaissance (C5ISR), Electronic Warfare (EW), and edge computing applications. Aligned with SOSA™, CMOSS, and OpenVPX™ standards, the 3U VPX module combines advanced La.
On June 17, 2026, we present a DCF analysis for Edwards Lifesciences Corp (EW). The company has shown a price performance of +1.2% over the past week, +8.8% ove
On Monday, the Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients with symptomatic severe aortic stenosis.
Key metrics vs top competitors for Edwards Lifesciences Corporation (EW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $94.82 | $54.6B | 51.81 | 11.55% | 17.69% | 10.52% | — | |
| $83.83 | $107.63B | 22.47 | 8.43% | 13.2% | 9.78% | — | |
| $95.84 | $166.94B | 25.76 | 5.67% | 13.91% | 12.09% | — | |
| $45.30 | $67.33B | 23.35 | 19.87% | 17.23% | 14.67% | — | |
| $313.38 | $120.14B | 37.31 | 11.16% | 13.21% | 15.1% | — | |
| $89.41 | $17.51B | 25.19 | 7.2% | 9.05% | 5.77% | — |
Edwards Lifesciences Corporation (EW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Edwards Lifesciences Corporation (EW) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 8, 2026·SEC
May 4, 2026·SEC
Apr 23, 2026·SEC
Get notified when EW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Edwards Lifesciences Corporation (EW) stock FAQ — growth, dividends, profitability & financials explained
Edwards Lifesciences Corporation (EW) reported $6.30B in revenue for fiscal year 2025. This represents a 597% increase from $905.0M in 1999.
Edwards Lifesciences Corporation (EW) grew revenue by 11.5% over the past year. This is steady growth.
Yes, Edwards Lifesciences Corporation (EW) is profitable, generating $1.09B in net income for fiscal year 2025 (17.7% net margin).
Edwards Lifesciences Corporation (EW) has a return on equity (ROE) of 10.5%. This is reasonable for most industries.
Edwards Lifesciences Corporation (EW) generated $1.09B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
